HUYABIO International Presents Positive Clinical Results from HBI-3000, a Novel Multi-ion Channel Blocker for Acute Atrial Fibrillation

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...